Published in Nat Genet on November 29, 2009
Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov (2012) 5.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A (2010) 2.91
Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J (2011) 2.75
Structure of the human Parkin ligase domain in an autoinhibited state. EMBO J (2013) 2.38
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J (2012) 2.36
Understanding multicellular function and disease with human tissue-specific networks. Nat Genet (2015) 2.04
Mechanism of phospho-ubiquitin-induced PARKIN activation. Nature (2015) 2.02
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet (2014) 2.01
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A (2011) 1.87
Parkin Regulates Mitosis and Genomic Stability through Cdc20/Cdh1. Mol Cell (2015) 1.49
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A (2011) 1.47
Parkinson's disease and cancer: two wars, one front. Nat Rev Cancer (2011) 1.45
STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev (2012) 1.38
Mithramycin is a gene-selective Sp1 inhibitor that identifies a biological intersection between cancer and neurodegeneration. J Neurosci (2011) 1.36
Leprosy and the human genome. Microbiol Mol Biol Rev (2010) 1.27
Cancer and neurodegeneration: between the devil and the deep blue sea. PLoS Genet (2010) 1.21
Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene (2010) 1.17
RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochem J (2014) 1.13
Mechanisms of genomic instabilities underlying two common fragile-site-associated loci, PARK2 and DMD, in germ cell and cancer cell lines. Am J Hum Genet (2010) 1.10
Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS One (2011) 1.09
Genome-wide approaches to schizophrenia. Brain Res Bull (2010) 1.09
Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. Hum Mol Genet (2014) 1.02
A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology (2010) 1.02
Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth. Nat Commun (2013) 0.99
CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc Natl Acad Sci U S A (2012) 0.99
Discovery of structural alterations in solid tumor oligodendroglioma by single molecule analysis. BMC Genomics (2013) 0.98
A Genome-Wide Association Study of Cutaneous Squamous Cell Carcinoma among European Descendants. Cancer Epidemiol Biomarkers Prev (2016) 0.97
Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion. Mol Genet Genomic Med (2014) 0.96
PINK1 and Parkin – mitochondrial interplay between phosphorylation and ubiquitylation in Parkinson's disease. FEBS J (2014) 0.94
Successful aging shows linkage to chromosomes 6, 7, and 14 in the Amish. Ann Hum Genet (2011) 0.92
Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle (2013) 0.91
The bad, the good, and the ugly about oxidative stress. Oxid Med Cell Longev (2012) 0.91
Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation. J Biol Chem (2014) 0.90
Regulation of parkin and PINK1 by neddylation. Hum Mol Genet (2012) 0.90
Studying a complex tumor: potential and pitfalls. Cancer J (2012) 0.87
Common fragile sites: genomic hotspots of DNA damage and carcinogenesis. Int J Mol Sci (2012) 0.87
Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem (2010) 0.87
Mitophagy mechanisms and role in human diseases. Int J Biochem Cell Biol (2014) 0.86
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
The familial Parkinson disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell Cycle (2010) 0.86
α-Synuclein expression selectively affects tumorigenesis in mice modeling Parkinson's disease. PLoS One (2011) 0.84
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome Med (2014) 0.84
Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma. Cancer Res (2015) 0.84
A recurrent mutation in PARK2 is associated with familial lung cancer. Am J Hum Genet (2015) 0.84
The ubiquitin signal and autophagy: an orchestrated dance leading to mitochondrial degradation. EMBO Rep (2016) 0.84
Metabolic, autophagic, and mitophagic activities in cancer initiation and progression. Biomed J (2016) 0.83
Discovering tumor suppressor genes through genome-wide copy number analysis. Curr Genomics (2010) 0.83
FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med (2016) 0.83
Alternative splicing generates different parkin protein isoforms: evidences in human, rat, and mouse brain. Biomed Res Int (2014) 0.82
Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. Neurogenetics (2011) 0.82
Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system. Cell Mol Life Sci (2014) 0.82
Parkin and mitophagy in cancer. Oncogene (2016) 0.81
Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Cell Mol Life Sci (2012) 0.81
The associations between Parkinson's disease and cancer: the plot thickens. Transl Neurodegener (2015) 0.81
Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol (2013) 0.81
Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. ScientificWorldJournal (2012) 0.81
Chronic Inflammation Links Cancer and Parkinson's Disease. Front Aging Neurosci (2016) 0.81
The association between Parkinson's disease and melanoma: a systematic review and meta-analysis. Transl Neurodegener (2015) 0.80
Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer. PLoS One (2013) 0.80
Mitochondria-Targeted Protective Compounds in Parkinson's and Alzheimer's Diseases. Oxid Med Cell Longev (2015) 0.80
Parkin structure and function. FEBS J (2015) 0.80
The Human Proteome Organization Chromosome 6 Consortium: integrating chromosome-centric and biology/disease driven strategies. J Proteomics (2013) 0.80
Is PARKIN parkinsonism a cancer predisposition syndrome? Neurol Genet (2015) 0.79
The ubiquitin-proteasome system in glioma cell cycle control. Cell Div (2012) 0.79
WWOX, large common fragile site genes, and cancer. Exp Biol Med (Maywood) (2015) 0.78
Bayesian pathway analysis of cancer microarray data. PLoS One (2014) 0.78
Pathologic and therapeutic implications for the cell biology of parkin. Mol Cell Neurosci (2015) 0.78
Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene. Curr Genomics (2014) 0.78
Parkin Regulates the Activity of Pyruvate Kinase M2. J Biol Chem (2016) 0.77
Cross Talk of Proteostasis and Mitostasis in Cellular Homeodynamics, Ageing, and Disease. Oxid Med Cell Longev (2016) 0.77
Knowledge-based analysis of genetic associations of rheumatoid arthritis to inform studies searching for pleiotropic genes: a literature review and network analysis. Arthritis Res Ther (2015) 0.77
A PARK2 polymorphism associated with delayed neuropsychological sequelae after carbon monoxide poisoning. BMC Med Genet (2013) 0.76
Multiple-level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease. Oncotarget (2016) 0.76
Mitochondrial Energy Metabolism and Thyroid Cancers. Endocrinol Metab (Seoul) (2015) 0.76
Genetic association of cyclooxygenase-2 gene polymorphisms with Parkinson's disease susceptibility in Chinese Han population. Int J Clin Exp Pathol (2015) 0.76
Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer (2012) 0.76
Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice. PLoS One (2015) 0.76
Expanding perspectives on the significance of mitophagy in cancer. Semin Cancer Biol (2017) 0.76
Gene polymorphisms are associated with clinical outcome in Chinese resected laryngeal carcinoma patients. Oncotarget (2016) 0.75
Genetics of childhood-onset schizophrenia. Child Adolesc Psychiatr Clin N Am (2013) 0.75
Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma. Neurol Genet (2016) 0.75
Molecular mechanisms and the conflict between courtship and aggression in three-spined sticklebacks. Mol Ecol (2016) 0.75
Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep (2016) 0.75
Identification of genetic modifiers of age-at-onset for familial Parkinson's disease. Hum Mol Genet (2016) 0.75
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases. Int J Mol Sci (2015) 0.75
Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia (2016) 0.75
The Relationship between Parkinson Disease and Brain Tumor: A Meta-Analysis. PLoS One (2016) 0.75
Polyubiquitination of apurinic/apyrimidinic endonuclease 1 by Parkin. Mol Carcinog (2016) 0.75
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
The Regulations of Deubiquitinase USP15 and Its Pathophysiological Mechanisms in Diseases. Int J Mol Sci (2017) 0.75
Molecular mechanisms orchestrating cyclin stability. Cell Cycle (2014) 0.75
Dysregulation of ubiquitin ligases in cancer. Drug Resist Updat (2015) 0.75
PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation. Mol Cell (2017) 0.75
Risk of lung cancer in Parkinson's disease. Oncotarget (2016) 0.75
Sorafenib Targets the Mitochondrial Electron Transport Chain Complexes and ATP Synthase to Activate the PINK1-Parkin Pathway and Modulate Cellular Drug Response. J Biol Chem (2017) 0.75
Germline mutations in DNA repair genes in lung adenocarcinoma. J Thorac Oncol (2017) 0.75
PARK2 negatively regulates the metastasis and epithelial-mesenchymal transition of glioblastoma cells via ZEB1. Oncol Lett (2017) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Consed: a graphical tool for sequence finishing. Genome Res (1998) 59.36
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell (1996) 15.19
PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res (1997) 13.48
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
PTEN: one gene, many syndromes. Hum Mutat (2003) 5.79
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature (2001) 5.07
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A (2000) 4.83
Deregulated cyclin E induces chromosome instability. Nature (1999) 4.75
Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature (2004) 4.35
Functional copy-number alterations in cancer. PLoS One (2008) 4.27
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science (2001) 4.18
Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem (2000) 3.86
Parkinson's disease. Lancet (2004) 3.08
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res (2007) 2.58
CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol Cell (2002) 2.53
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron (2003) 2.49
Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene (2003) 2.44
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet (2006) 2.24
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet (2005) 2.11
Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep (2003) 2.01
A survey of homozygous deletions in human cancer genomes. Proc Natl Acad Sci U S A (2005) 1.94
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet (2003) 1.83
Structure of the Parkin in-between-ring domain provides insights for E3-ligase dysfunction in autosomal recessive Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.73
Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer (2005) 1.72
Cyclin E in human cancers. FASEB J (1999) 1.62
Cyclin E overexpression impairs progression through mitosis by inhibiting APC(Cdh1). J Cell Biol (2007) 1.58
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Genomic mutation consequence calculator. Bioinformatics (2007) 1.48
Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol (2005) 1.47
Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res (2004) 1.45
Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem (2008) 1.42
Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J Clin Immunol (1996) 1.37
Molecular interaction between parkin and PINK1 in mammalian neuronal cells. Mol Cell Neurosci (2009) 1.36
Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci (2009) 1.34
Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. Neoplasia (2008) 1.32
Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer (1996) 1.29
Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J Neurochem (2008) 1.25
Occurrence of different cancers in patients with Parkinson's disease. BMJ (1995) 1.23
Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm Genome (2000) 1.11
Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer (2004) 1.05
Identification of molecular determinants required for interaction of ubiquitin-conjugating enzymes and RING finger proteins. Eur J Biochem (2001) 0.99
Parkin interacts with the proteasome subunit alpha4. FEBS Lett (2005) 0.99
Both SCF(Cdc4alpha) and SCF(Cdc4gamma) are required for cyclin E turnover in cell lines that do not overexpress cyclin E. Cell Cycle (2008) 0.98
Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication. Neurodegener Dis (2008) 0.96
Parkin regulates Eg5 expression by Hsp70 ubiquitination-dependent inactivation of c-Jun NH2-terminal kinase. J Biol Chem (2008) 0.96
Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J Neurochem (2002) 0.93
Parkinson's disease: from causes to mechanisms. C R Biol (2005) 0.89
E3 ubiquitin-protein ligase activity of Parkin is dependent on cooperative interaction of RING finger (TRIAD) elements. J Biomed Sci (2001) 0.86
Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin. Methods Mol Biol (2005) 0.84
Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved? Int J Gynecol Pathol (2008) 0.78
Human MicroRNA targets. PLoS Biol (2004) 34.51
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell (2008) 28.29
Integration of biological networks and gene expression data using Cytoscape. Nat Protoc (2007) 27.10
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
MicroRNA targets in Drosophila. Genome Biol (2003) 23.59
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
International network of cancer genome projects. Nature (2010) 20.35
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The HUPO PSI's molecular interaction format--a community standard for the representation of protein interaction data. Nat Biotechnol (2004) 16.08
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Characterizing gene sets with FuncAssociate. Bioinformatics (2003) 14.10
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med (2005) 13.40
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Identification of virus-encoded microRNAs. Science (2004) 12.56
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
The BioPAX community standard for pathway data sharing. Nat Biotechnol (2010) 9.19
Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res (2010) 9.18
A novel class of small RNAs bind to MILI protein in mouse testes. Nature (2006) 8.80
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 8.66
The Systems Biology Graphical Notation. Nat Biotechnol (2009) 8.53
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Gene expression profiling of gliomas strongly predicts survival. Cancer Res (2004) 7.79
Mutations in GNA11 in uveal melanoma. N Engl J Med (2010) 7.52
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol (2010) 7.15
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med (2006) 7.10
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A (2009) 6.78
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol (2004) 6.44
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Pathguide: a pathway resource list. Nucleic Acids Res (2006) 6.05
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res (2006) 5.69